Clinical Trial

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-04-25; most recent amendment 2025-12-19.
Status change: Not Yet Recruiting → Recruiting 2025-06-11
Trial Details
NCT Number NCT06947993
Lead Sponsor Novartis Pharmaceuticals
Conditions Atopic Dermatitis
Enrollment 224 participants
Start Date 2025-05-16
Primary Completion 2028-11-27 (estimated)
Study Completion 2028-12-22 (estimated)
Updated on ClinicalTrials.gov 2025-12-22